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Abstract
Stem cell factor (SCF) mediated KIT receptor activation plays a pivotal role in mast cell growth, maturation and survival.
However, the signaling events downstream from KIT are poorly understood. Mast cells express multiple regulatory subunits
of class 1A PI3Kinase (PI3K) including p85a, p85b, p50a, and p55a. While it is known that PI3K plays an essential role in mast
cells; the precise mechanism by which these regulatory subunits impact specific mast cell functions including growth,
survival and cycling are not known. We show that loss of p85a impairs the growth, survival and cycling of mast cell
progenitors (MCp). To delineate the molecular mechanism (s) by which p85a regulates mast cell growth, survival and
cycling, we performed microarray analyses to compare the gene expression profile of MCps derived from WT and p85a-
deficient mice in response to SCF stimulation. We identified 151 unique genes exhibiting altered expression in p85a-
deficient cells in response to SCF stimulation compared to WT cells. Functional categorization based on DAVID
bioinformatics tool and Ingenuity Pathway Analysis (IPA) software relates the altered genes due to lack of p85a to
transcription, cell cycle, cell survival, cell adhesion, cell differentiation, and signal transduction. Our results suggest that p85a
is involved in mast cell development through regulation of expression of growth, survival and cell cycle related genes.
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Introduction
Mast cells are critical mediators of inflammation, innate
immunity and host defense that originate from multipotent stem
cells in the bone marrow (BM) [1]. Mast cells have been implicated
in inflammatory diseases including multiple sclerosis [2], rheuma-
toid arthritis [3] and coronary artery disease [3] and inflammatory
diseases [4]. Emerging data also suggests a crucial role for mast
cells in tumor progression and angiogenesis [5].
The homing, growth, differentiation and survival of mast cell
are regulated by complex network of growth factors and
transcription factors. While several cytokines influence the growth,
survival and maturation of mast cells, SCF and its interaction with
KIT receptor are critical for normal mast cell development and
function. Mice that lack either KIT or SCF are completely devoid
of mature mast cells in all tissues [6,7,8]. However, the
intracellular signals downstream from KIT in regulating both
growth and survival of mast cells are poorly understood. Recent
studies have shown that PI3Kinase (PI3K), which binds to tyrosine
at position 719 in murine KIT (at 721 in human KIT) through its
regulatory subunit contributes substantially to KIT mediated mast
cell functions [9,10]. Class IA PI3Kinase is a lipid kinase made up
of p85 regulatory subunit(s) and p110catalytic subunit(s) [11,12].
In hematopoietic cells, four regulatory (p85a, p85b, p55a and
p50a) and three catalytic (p110a, p110b and p110d) subunits of
class IA PI3K are expressed. Utilizing genetic and genomic
approaches, we evaluate the role of p85a in mast cell development
and functions in response to SCF stimulation. We provide
evidence for the critical role of p85a in mast cell growth, survival
and cycling; and possible pathways by which p85a regulates mast
cell functions in response to SCF stimulation.
Results
Deficiency of p85a results in reduced mast cell growth in
response to SCF
While mast cells express various regulatory subunits of Class 1A
PI3K including p85a, p85b, p55a and p50a, the physiological role
of these subunits in mast cell growth, survival and cycling are not
known. Here we sought to evaluate the specific role of p85a in
mast cell growth, survival and cycling in response to SCF
stimulation. We generated in vitro bone marrow–derived mast
cells (BMMC) from WT and p85a2/2 mice. Loss of p85a in
p85a2/2 BMMCs was confirmed by western blotting (Data not
shown). To assess the contribution of p85a in mast cell growth,
BMMCs from WT and p85a2/2 mice were subjected to
proliferation assay in the presence or absence of SCF. As seen in
Figure 1, BMMCs from WT and p85a2/2 mice grown in the
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tion. While WT BMMCs demonstrated a significant increase in
growth in the presence of SCF, deficiency of p85a resulted in
complete loss of SCF mediated growth (Figure 1). These results
suggest that the p85a regulatory subunit is critical for SCF-
induced mast cell growth.
Reconstitution of p85a into p85a2/2 MCps completely
corrects defective SCF-mediated growth
To determine whether the complete loss of SCF-mediated mast
cell growth in p85a2/2 cells is due to loss of p85a, we transduced
mast cell progenitors (MCp) from WT and p85a2/2 mice with
vector or p85a and cells were sorted to homogeneity based on
EGFP expression. Sorted cells were starved and analyzed
proliferation in the presence or absence of SCF by thymidine
incorporation. As expected, while WT cells transduced with vector
showed increase in growth in the presence of SCF, vector
transduced p85a2/2 cells showed complete loss of growth
(Figure 2). As seen in Figure 2, restoring the expression of p85a
in p85a-deficient MCps completely restored SCF-induced growth.
These results suggest that the defective SCF-mediated growth
observed in p85a2/2 BMMCs is due to specific loss of p85a.
Defective survival of p85a-deficient BMMCs in response
to SCF
In an effort to further determine the mechanism(s) behind
reduced SCF-mediated growth of p85a2/2 cells, BMMCs from
WT and p85a2/2 mice were subjected to apoptosis analysis
in the presence or absence of SCF. BMMCs from WT and
p85a2/2 mice were starved for 6 hours in serum- and cytokine-
free media and grown in the presence or absence of SCF. After
48 hours, apoptosis was assessed by staining the cells with
antibodies to annexin V and 7-AAD followed by flow cytometry
analysis. As seen in Figure 3, less than 10% of BMMCs from WT
and p85a2/2 mice survived in the absence of growth factors as
determined by the presence of annexin V and 7-AAD negative
cells. While WT BMMCs showed significant increase in survival
in the presence of SCF, deficiency of p85a resulted in significant
reduction in SCF-mediated survival (Figure 3). These results
suggest that p85a acts as a positive regulator of mast cell survival
in response to SCF.
Reduced cycling of p85a-deficient BMMCs in response to
SCF
We then examined cell cycle progression in WT and p85a2/2
BMMCs in response to SCF stimulation. BMMCs from WT and
p85a2/2 mice were starved for 6 hours in serum- and cytokine-
free media and grown in the presence or absence of SCF. After
48 hours, cells were labeled with propidium iodide and cycling
was analyzed by flow cytometry. As seen in Figure 4, while SCF
stimulation enhanced the cycling of WT BMMCs, p85a2/2 cells
showed impaired cell cycle progression and S phase entry. These
results suggest that p85a plays a critical role in cycling of mast cells
in response to SCF.
Deficiency of p85a alters the expression of genes related
to growth and survival in MCps
Our results suggest that p85a subunit plays a critical role in
proliferation, survival and cycling of BMMCs. To further
determine the underlying molecular mechanism for the action of
p85a on growth and survival, we performed microarray analyses
to compare the gene expression profile of MCps derived from WT
and p85a-deficient mice when stimulated with SCF (Figure 5). To
determine significantly altered genes in p85a-deficient MCps
compared to WT, we calculated the p value for gene expression
pattern based on Student’s t-test using Partek software with the
following criteria: change in expression of at least 1.5-fold and
p,0.05. This analysis identified 151 unique genes exhibiting
altered expression in p85a2/2 cells (Table S1). Raw data and
normalized expression data are available for download from Gene
Expression Omnibus (http://ncbi.nlm.nih.gov/geo, accession
number GSE32410).
To validate the microarray results, we analyzed the expression
of four important genes (Lin9, Rrm1, Cbx5, and Taok3) in MCps
derived from WT and p85a-deficient mice when stimulated with
Figure 1. Deficiency of p85a results in reduced SCF-mediated
BMMC growth. BMMCs from WT and p85a2/2 mice were cultured in
the presence of IL-3 (10 ng/mL) for 3 weeks. Cells were starved for
6 hours in serum- and cytokine-free media and cultured in the presence
or absence of SCF (50 ng/mL) for 48 hours. Then, proliferation was
evaluated by [
3H] thymidine incorporation. Bars represent the mean
[
3H] thymidine incorporation in BMMCs (CPM 6 SD) from one
representative experiment performed in quadruplicate. Similar results
were observed in three independent experiments. *p,0.01, WT vs.
p85a2/2.
doi:10.1371/journal.pone.0028979.g001
Figure 2. Reconstitution of p85a in to p85a2/2 MCps
completely corrects defective SCF-mediated growth. WT and
p85a2/2 MCps transduced with vector or p85a were sorted to
homogeneity based on EGFP expression and cultured in the presence
of IL-3 (10 ng/mL). Cells were starved for 6 hours in serum- and
cytokine-free media and cultured in the presence or absence of SCF
(50 ng/mL). After 48 hours, proliferation was evaluated by a [
3H]
thymidine incorporation assay. Bars represent the mean [
3H] thymidine
incorporation in BMMCs (CPM 6 SD) from one representative
experiment performed in quadruplicate. Similar results were observed
in three independent experiments. *p,0.01, WT-vector vs. p85a-/–
vector; *p,0.01, p85a-/–vector vs. p85a-/–p85a.
doi:10.1371/journal.pone.0028979.g002
p85a in KIT Receptor Signaling
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consistent with our microarray results, Lin9 and Rrm1 genes were
up regulated 1.06 and 2.85 fold, respectively, in p85a-deficient
MCps compared to WT MCps. Likewise, Cbx5 and Taok3 genes
were down regulated 2.35 and 5.19 fold, respectively, in p85a-
deficient MCps compared to WT MCps.
To further make the microarray data more meaningful in the
context of how they alter mast cell biology, we functionally
categorized these genes based on the DAVID bioinformatics tool,
and Ingenuity Pathway Analysis (IPA) software. David tool relates
altered genes due to lack of p85a to transcription, cell cycle, cell
adhesion, cell differentiation, cell survival and signal transduction
(Table 1 and Table 2). Ingenuity Pathway Analysis (IPA) software
associated altered gene in p85a2/2 with cell growth (Figure 7),
cell survival (Figure 8), and the cell cycle (Figure 9) networks.
Identification of these four principal networks is relevant to this
study, as our functional data suggest that mast cells lacking the
p85a regulatory subunit display defective growth, altered survival
and differentiation (see below). The IPA network provides further
information on additional genes including Pdgfb, Akt, Hnf4A, Stat3,
Tgfb, Myc, Brca1, Crebbp (Figure 6, 7, 8). These genes identified by
IPA tool, which are related to the altered genes in p85a2/2 per
the microarray data, could also play roles in mast cell biological
functions in response to SCF stimulation. Genetic disruption of
p85a resulted in upregulation of tumor suppressor gene Lin9 (Lin-
9 homolog); and Rrm1 (Ribonucleotide Reductase M1), which is
reported to induce the expression of PI3K negative regulator
PTEN [13]. Of the down regulated genes - Nsd1, which is related
to acute myeloid leukemia and prostate cancer [14]; Tgfb-
inducible Fbln5, which are important in cell growth, migration and
cell adhesion [15]; Taok3 (Tao kinase 3), which has been reported
to activate ERK1/ERK2 [16]; and Pim3 (Pim3 kinase) which has
been reported to positively regulate cell proliferation and survival,
down regulation of which might contribute significantly to
increased apoptosis in p85a-deficient cells are of significance for
future studies [17].
Figure 3. Defective survival of p85a-deficient BMMCs. BMMCs from WT and p85a2/2 mice were starved for 6 hours in serum- and cytokine-
free media and cultured in the presence or absence of SCF (50 ng/mL). After 48 hours, cells were stained with phycoerythrin-conjugated annexin V
and 7-AAD followed by flow cytometry analysis. Shown is a representative dot blot (Left panel) and bar graph (Right panel) demonstrating
percentage of annexin V and 7-AAD negative cells in the presence and absence of SCF. Similar results were observed in three independent
experiments. *p,0.05, WT vs. p85a2/2.
doi:10.1371/journal.pone.0028979.g003
Figure 4. Reduced cycling of p85a-deficient BMMCs. BMMCs from WT and p85a2/2 mice were starved for 6 hours in serum- and cytokine-free
media and cultured in the presence or absence of SCF (50 ng/mL). After 48 hours, cells were stained with propidium iodide followed by flow
cytometry analysis as described in methods. Shown is a representative histogram (Left panel) and bar graph (Right panel) demonstrating the
percentage of cells in S phase in the presence or absence of SCF. Similar results were observed in two independent experiments. *p,0.05, WT vs.
p85a2/2.
doi:10.1371/journal.pone.0028979.g004
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Emerging data have demonstrated the crucial role of SCF-
mediated KIT signaling in mast cell development [8,18,19,20,21].
Downstream from KIT receptor, PI3Kinase (PI3K) plays a critical
role in mast cell development and its functions including growth,
survival, differentiation, adhesion and migration [10]. PI3K is a
complex of regulatory (p85) and catalytic subunits (p110), which
gets activated upon binding to KIT receptor via its regulatory
subunit. Current dogma in PI3K is that the primary function of
regulatory subunits of class IA PI3K is mainly to stabilize and
activate the different p110 catalytic subunits. Recent studies have
also shown the involvement of PI3K in abnormal KIT signaling
due to activating KIT mutation (KITD816V in human and
Figure 5. Methodology followed for microarray analysis. Low density mononuclear cells (LDMNC) were isolated from three pairs of WT and
p85a2/2 mice and cultured independently in the presence of IL-3 (10 ng/mL) for 1 week. KIT and IgE receptor double positive mast cells were sorted
by using FACS. Sorted mast cells were stimulated with SCF (100 ng/mL) for 48 hours and then sent for microarray analysis for gene expression
profiling.
doi:10.1371/journal.pone.0028979.g005
Figure 6. Validation of microarray analysis. Low density
mononuclear cells (LDMNC) were isolated from WT and p85a2/2 mice
and cultured in the presence of IL-3 (10 ng/mL) for 1 week. KIT and IgE
receptor double positive mast cells were sorted by using FACS. Sorted
mast cells were stimulated with SCF (100 ng/mL) for 48 hours and
mRNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Valencia,
CA). Qualitative real-time PCR was performed for the indicated genes
using primers from Applied Biosystems as described in methods.
Results show fold change of indicated genes, normalized to Actin,i n
p85a-deficient MCps compared to WT MCps.
doi:10.1371/journal.pone.0028979.g006
Table 1. Functional categories of genes upregulated in
p85a2/2 MCp’s in response to SCF stimulation.
Functional
Category
Gene
Symbol Gene Name
Fold
Change
Ubl conjugation
pathway
Senp6 Sumo/Sentrin Specific Peptidase 6 1.62
Asb5 Ankyrin Repeat And Socs Box-
Containing protein
2.80
Ubr2 Riken Cdna E130209G04 gene 1.84
Proteolysis Senp6 Sumo/Sentrin Specific Peptidase 6 1.62
Ubr2 Riken Cdna E130209G04 gene 1.84
Klk6 Kalikrein 6 1.92
Rnf150 Ring Finger Protein 150 4.39
Cell Surface
receptor
Il23r Interleukin 23 Receptor 1.74
Olfr1107 Olfactory Receptor 1107 1.73
Sufu Suppressor of Fused Homolog 2.11
Olfr1179 Olfactory Receptor 1179 1.58
Gpr21 G Protein-Coupled Receptor 21 1.57
Cell cycle Bub3 Budding uninhibited by
Benzimidazoles 3 homolog
20.9
Ubr2 Riken Cdna E130209G04 gene 1.84
Lin9 Lin-9-Homolog (C. Elegans) 4.16
Cetn1 Centrin 1 2.63
Atp6v1b2 Atpase, H+ Transporting,
Lysosomal V1 Subunit B2
1.67
Rrm1 Ribonucleotide Reductase M1 1.67
Agps Alkylglycerone Phosphate
Synthase
2.30
Cetn1 Centrin 1 2.63
doi:10.1371/journal.pone.0028979.t001
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including mastocytosis and mast cell leukemia [22,23].
In this study, we evaluated the role of p85a regulatory subunit
in mast cell growth, survival and cycling. We showed that genetic
disruption of p85a results in defective SCF-mediated mast cell
growth, survival and cycling. The defective SCF-mediated mast
cell growth was observed irrespective of the presence of other
PI3K regulatory subunits including p85b, p55a and p50a
suggesting that p85a might play a unique role in SCF-mediated
mast cell growth. These results were further supported by the fact
that reconstitution of p85a2/2 BMMCs with p85a completely
corrects KIT-induced proliferation. These findings suggest that the
defective SCF-mediated growth observed in p85a2/2 BMMCs is
a result of specific loss of p85a and not due to quantitative
reduction in the overall expression of regulatory subunits.
To further identify the molecular mechanism (s) by which p85a
regulates mast cell growth, survival and cycling, we performed
microarray analyses to compare the gene expression profile of
MCps derived from WT and p85a-deficient mice in response to
SCF stimulation. We identified 151 unique genes that were altered
in p85a-deficient MCps compared to WT MCps in response to
SCF stimulation. Ingenuity pathway analysis was performed on
these 151 altered genes, which revealed some interesting pathways
that are effected due to deficiency of p85a including AKT and
PDGF pathway which is important in cell growth and survival
[24,25]; IL-6, important in cell growth [26]; and Myc which is
important in cell growth and survival [27]; TGF-b pathway which
is important in cell migration [28]. Furthermore, the deficiency of
p85a also enhances apoptotic signals in mast cells by upregulating
genes involved in proteolysis and UBL conjugation pathway,
which might be partly responsible for significantly reduced
proliferation in response to SCF stimulation. Moreover, altered
expression of cell cycle genes Rrm1 and Taok3 could also be
important in regulating mast cell growth. Rrm1 is a negative
regulator of PI3K activity through induction of PTEN expression
[29], the expression of which is enhanced in absence of p85a
regulatory subunit. Taok3 is an enhancer of ERK activity [16],
which is down regulated in absence of p85a. Thus p85a might
directly or indirectly via. HNF4A regulate the expression of these
genes in response to SCF stimulation. Moreover, p85a might
regulate mast cell migration via. TGF-b pathways as indicated by
IPA result.
These findings have high significance in clinical implications as
mast cells are increasingly recognized as key components in
regulating tumor progression as well as inflammatory diseases
including multiple sclerosis [2], rheumatoid arthritis [3] and
coronary artery disease [3] and inflammatory diseases [4].
Previous studies have also shown increased mast cell infiltration
Table 2. Functional categories of genes downregulated in p85a2/2 MCp’s in response to SCF stimulation.
Functional Category Gene Symbol Gene Name Fold Change
Transcription Regulation Nsd1 Nuclear receptor-binding set domain protein 1 22.11
Arntl2 Aryl hydrocarbon receptor nuclear translocator-like 21.72
Pcgf2 Polycomb group ring finger 2 21.90
Tcf20 Transcription factor 20 23.50
Pou4f3 Pou domain, class 4, transcription factor 3 21.55
Uimc1 Retinoid x receptor interacting protein 110 23.06
Protein Kinase Activity Pim3 Proviral integration site 3 23.63
Taok3 Tao kinase 3 23.41
Dyrk1a Dual-specificity tyrosine phosphorylation regulated kinase 1a 22.13
Cell differentiation Sema3d Riken cDNA 4631426b19 gene 22.26
Psme4 Proteasome activator subunit 4 21.77
Mbnl1 Muscle blind-like 1 (drosophila) 22.03
Pou4f3 Pou domain, class 4, transcription factor 3 21.55
Cell adhesion Cdh8 Cadherin 8 27.09
Fbln5 Fibulin 5 21.64
Col2a1 Procollagen, type ii alpha 1 21.56
Signal transduction Pofut1 Protein o-fucosyl transferase 1 22.66
Arntl2 Aryl hydrocarbon receptor nuclear translocator-like 2 21.72
Taok3 Tao kinase 3 23.41
Arhgef3 Rho guanine nucleotide exchange factor 3 22.18
Rabl2a Rab, member of ras oncogene family-like 2a 21.58
Post-translational protein modification Nsd1 Nuclear receptor binding set domain protein 1 22.11
Pim3 Proviral integration site 3 23.63
Taok3 Tao kinase 3 23.41
Pcgf2 Polycomb group ring finger 2 21.90
Fbxo3 F-box only protein 3 21.90
Dyrk1a Dual-specificity tyrosine phosphorylation regulated kinase 1a 22.13
doi:10.1371/journal.pone.0028979.t002
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provides insight into proteins that regulate SCF-mediated mast cell
growth, survival, and cycling, which can be further explored to
develop future therapeutic treatments to human diseases involving
mast cells.
Materials and Methods
Cytokines, Antibodies and Reagents
Recombinant murine interleukin-3 (IL-3) and stem cell factor
(SCF) were purchased from Pepro Tech (Rocky Hill, NJ).
Phycoerythrin (PE)-conjugated KIT antibody, fluorescence iso-
thyocyanate (FITC)–conjugated IgE receptor antibody, PE-
conjugated annexin V antibody and 7-Amino actinomycin D (7-
AAD) were purchased from BD Biosciences (San Jose, CA).
Rabbit anti-p85 pan antibody (clone UB93-3) and mouse
anti-p85a–specific antibody (clone AB6) were purchased from
Upstate Biotechnology Inc., (Lake Placid, NY). Retronectin was
purchased from Takara (Madison, WI). Iscove’s Modified
Dulbecco’s Medium (IMDM) was purchased from Invitrogen
(Carlsbad, CA). [
3H] thymidine was purchased from PerkinElmer
(Boston, MA).
Mice
p85a2/2 mice have been previously described_ENREF_28
[32]. All mice were maintained under specific pathogen-free
conditions at the Indiana University Laboratory Animal Research
Center (Indianapolis, IN). All studies were approved by the
Indiana University Laboratory Animal Resource Center (Study #
3137 and Study # 937).
Figure 7. Ingenuity Pathway Analysis (IPA) of cell growth related genes in p85a2/2 MCp’s in response to SCF stimulation. Altered
genes in p85a
2/2 cells after SCF stimulation were analyzed by IPA software to analyze their closely associated gene network. Significantly altered cell
growth related genes in p85a2/2 MCp’s in response to SCF stimulation were indicated.
doi:10.1371/journal.pone.0028979.g007
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Cells were harvested from wild-type C57BL/6 mice by flushing
out the spleen using IMDM media and the low density cells were
collected after density gradient centrifugation using Histopaque
1083. Total RNA was isolated from these cells using QIAGEN
RNeasy Kit. Total RNA isolated was quantified and also purity
was measured using spectrophotometer. cDNA for RT-PCR was
prepared from 5 mg of total RNA using SuperScript First-Strand
Synthesis System as per instructions (Invitrogen, Carlsbad, CA).
1 mg of cDNA was used to isolate gene of interest by PCR
amplification with specific primers (see below).
Construction of p85a subunit
RNA was isolated and cDNA was prepared from murine spleen.
Following synthesis of cDNA, the following primers were used for
p85a PCR: forward, 59-GAATTCATGTACCCATACGATGT
TCCAGATTACGCTATGAGTGCAGAGGGCTACCAG; re-
verse, 59-CTCGAGTCATCGCCTCTG TTGTGCATATAC.
Restriction sites used for cloning purposes have been underlined.
PCR was performed using the following conditions: an initial
denaturation step at 94uC for 2 min followed by 23 cycles of 94uC
for 30 s, 60uC for 1 min, and 72uC for 2 min, with a final step of
72uC for 7 min. The plasmid have a HA tag at the amino
terminus and was cloned into the EcoRI/XhoI site upstream of an
internal entry site and the enhanced green fluorescence (EGFP)
protein containing bi-cistronic retroviral vector MIEG3.
Preparation of retroviral supernatants for transduction
Retroviral supernatants for transduction of primary mast
cell progenitors (MCp) were generated using the Phoenix
ecotropic packaging cell line (provided by Dr. Garry Nolan,
Stanford University, Stanford, CA) transfected with retroviral
vector plasmids using a calcium phosphate transfection kit
(Invitrogen, Carlsbad, CA) [33]. Supernatants were collected
after 48 hours of transfection and filtered through 0.45 uM
membranes.
Figure 8. Ingenuity Pathway Analysis (IPA) of cell survival related genes in p85a2/2 MCp’s in response to SCF stimulation. Altered
genes in p85a
2/2 cells after SCF stimulation were analyzed by IPA software to analyze their closely associated gene network. Significantly altered cell
survival related genes in p85a2/2 MCp’s in response to SCF stimulation were indicated.
doi:10.1371/journal.pone.0028979.g008
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(BMMC) from wildtype (WT) and p85a2/2 mice
To generate BMMCs, low density mononuclear cells (LDMNC)
were isolated from WT and p85a2/2 mice and cultured in
IMDM supplemented with 10% FBS, 2% penicillin/streptomycin
and 10 ng/mL of IL-3 for 3–4 weeks. These cells were used at
different stages for growth, survival and cell cycle experiments.
Expression of vector or p85a into mast cell progenitors
(MCp)
To express vector or p85a subunit in MCps, LDMNCs were
collected from WT and p85a2/2 mice, and pre-stimulated in
IMDM supplemented with 20% FBS, 2% penicillin/streptomycin,
and cytokines (100 ng/mL SCF and 10 ng/mL IL-3) for 48 hours
prior to retroviral infection on fibronectin fragments (Retronectin)
in non-tissue culture plates. On third day, MCps were infected
with 4 mL of high-titer retroviral supernatants for vector or p85a
prepared as described above. A second shot of viral infection was
given twenty four hours later. Forty-eight hours after the second
infection, cells expressing EGFP were sorted and utilized to
perform all experiments.
Proliferation assay
Cell proliferation was assessed by conducting a thymidine
incorporation assay as described [34]. Briefly, cells were washed
twice with warm IMDM and starved in IMDM supplemented
with 0.2% BSA for 6 to 7 hours. 5610
4 cells were plated in a 96-
well plate in 200 ml of IMDM supplemented with 10% fetal bovine
serum plus 2% penicillin/streptomycin in the presence or absence
of SCF. Cells were cultured for 48 hours and subsequently pulsed
Figure 9. Ingenuity Pathway Analysis (IPA) of cell cycle related genes in p85a2/2 MCp’s in response to SCF stimulation. Altered
genes in p85a
2/2 cells after SCF stimulation were analyzed by IPA software to analyze their closely associated gene network. Significantly altered cell
cycle related genes in p85a2/2 MCp’s in response to SCF stimulation were indicated.
doi:10.1371/journal.pone.0028979.g009
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3H] thymidine for 6 to 8 hours at 37uC. Cells
were harvested using an automated 9-well cell harvester (Brandel;
Gaithersburg, MD) and thymidine incorporation was determined
as counts per minute (CPM).
Apoptosis and Cell Cycle
To determine the cell cycle and apoptosis, cells were washed 2
times with IMDM to remove any serum or cytokines. The cells
were then starved for 7 hours in IMDM supplemented with 0.2%
BSA. Then, 0.2610
6 cells were cultured in the presence or
absence of SCF (100 ng/mL). After 48 hours, cells were washed
with PBS and the percentage of cell death was determined by
annexin V and 7-AAD staining. Cells were re-suspended in 16
annexin V binding buffer and incubated for 30 min at 4uC. Cells
were incubated with 5 mL each of annexin V and 7-AAD for
20 min at room temperature in the dark. After incubation,
percentage of apoptotic cells (annexin V and 7-AAD positive) was
determined using flow cytometry. For cell cycle analysis, cells
were labeled by propidium iodide (PI) and analyzed by flow
cytometry.
Sample preparation for microarray analysis
LDMNCs were harvested from 3 independent WT and
p85a2/2 mice and cultured in IMDM supplemented with 10%
fetal bovine serum, 2% penicillin/streptomycin, and 10 ng/mL of
IL-3 for 7 days. Cells were collected by centrifugation, re-
suspended in 200 mL PBS containing 0.2% BSA, and then
incubated with 5 mg of anti-PE-KIT and anti-FITC-IgE antibody
for 30 min at 4uC. Cells were washed with PBS containing 0.2%
BSA to remove any unbound antibodies. The mast cell population
that demonstrated double expression of KIT and IgE receptors
was then sorted and collected. The sorted cells were then
stimulated with SCF (100 ng/mL) for 48 hours, after which, they
were pelleted, frozen immediately and stored at 280uC until
further use for microarray analysis.
Microarray processing and data analysis
Frozen mast cells stimulated with SCF (100 ng/mL) from 3
independent WT and p85a2/2 mice (as described above) were
sent to Miltenyi Biotech to carry out the microarray analysis. Due
to smaller sample size (,10,000 cells), super-amplification
technology was used for the analysis. This amplification was
based on a global PCR protocol using mRNA-derived cDNA.
mRNA was isolated via magnetic bead technology. Amplified
cDNA from the mRNA samples was quantified and quality was
evaluated by capillary electrophoresis on an Agilent 2100
Bioanalyzer platform (Agilent Technologies; Santa Clara, CA).
250 ng of WT and p85a2/2 cDNAs was labeled with fluorescent
dye cy3 or cy5 and simultaneously hybridized overnight (17 hours,
65uC) to an Agilent whole-mouse genome oligo microarray
4644 K. In order to avoid differential incorporation of the 2
dyes into target samples, dye incorporation rate was carefully
monitored. To avoid breakdown of cy5 by ozone, an ozone-free
microarray facility in Miltenyi Biotech was maintained with
specially installed ozone extractors. Subsequently, microarrays
were washed and signals were detected using Agilents DNA
microarray scanner. Probe-set intensities were obtained and a
quantile normalization procedure was used to adjust for the
difference in probe intensity distribution across different chips. For
our analysis, we included genes that showed a fold-change .1.5
and p,0.05.
Quantitative PCR analysis
Total RNA was isolated using the RNeasy Minikit (Qiagen) and
then treated with TURBO DNase (Ambion) to remove genomic
DNA. Single-stranded cDNA was synthesized using Omniscript
reverse transcriptase (Qiagen) according the manufacturer’s
instructions. Gene expression was analyzed on an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems) using
TaqMan Gene Expression Assays (Applied Biosystems) and the
FastStart Universal Probe Master Mix (Roche). For data analysis,
DCT values were calculated using ß-Actin (Actb) expression as an
internal control. Fold change between wild-type and p85a samples
was calculated using the 2
(DDCT) method. Data are representative
of three technical replicates for one biological sample. Expression
was principally confirmed by two biological replicates.
Statistics
All graphical data was evaluated by paired Student t- test and
results were considered significantly different with p-value ,0.05.
All data are represented as mean values 6 standard deviations
(SD).
Supporting Information
Table S1 List of genes altered in p85a2/2 MCp’s in
response to SCF stimulation. Low density mononuclear cells
(LDMNC) were isolated from three pairs of WT and p85a2/2
mice and cultured independently in the presence of IL-3 (10 ng/
mL) for 1 week. KIT and IgE receptor double positive mast cells
were sorted by using FACS. Sorted mast cells were stimulated with
SCF (100 ng/mL) for 48 hours and then sent for microarray
analysis for gene expression profiling. Altered expression of genes
in p85a2/2 MCp’s in response to SCF stimulation compared to
WT controls were listed in Table S1.
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